BONE TARGETING AGENTS IN PREVENTION OF SKELETAL-RELATED EVENTS IN METASTATIC CANCERS OF SOLID TUMOURS: AN ECONOMIC EVALUATION

Authors

  • HANIN FARHANA KAMARUZAMAN Malaysian Health Technology Assessment Section (MaHTAS), Ministry of Health Malaysia
  • Atikah Shaharudin
  • Sharifa Ezat Wan Puteh
  • Zafar Ahmed
  • Junainah Sabirin

DOI:

https://doi.org/10.17501/23246735.2019.5102

Keywords:

skeletal-related events, bone metastases, cost-effectiveness analysis, economic evaluations

Abstract

Skeletal related events (SREs) are skeletal complications from bone metastases such as spinal cord compression, pathological fracture, palliative radiation to the bone and bone surgery. These events resulted in greatest morbidity which affecting patients’ quality of life over the years and may increase healthcare cost in treating SREs. Therefore, preventing SREs may reduce the economic burden to health care. Bone targeting agents (BTA) significantly delayed time-to-first SREs and reduced the risk of first and subsequent SREs in majority of cancers. Among all BTA, denosumab and zoledronic acid are the most effective and commonly used in preventing SREs. The objective of this evaluation was to assess the cost-effectiveness  of  BTA in  prevention  of  SREs in  metastatic cancer  of  solid  tumours and its financial implication. The economic evaluation was designed from provider perspective (Ministry of Health, Malaysia) using literature-based Markov model to compare the costs and quality adjusted life years (QALY) for hypothetical cohort of patients with primary solid tumour with bone metastases. Based on the model, the use of BTA in preventing skeletal-related events among solid tumour patients with bone metastases is a cost-effective strategy.  Within this evaluation, the most cost-effective option was 12-weekly intravenous Zoledronic acid, yielding an incremental cost-effectiveness ratio of RM 4,969 per QALY gained. The estimated total financial implication for this strategy was RM 8.8 million per year. In conclusion, 12-weekly Zoledronic acid is the most cost-effective option in preventing SREs in solid tumour cancer patients with bone metastasis.

Downloads

Download data is not yet available.

References

ACTION Study Group, 2017. Health-related quality of life and psychological distress among cancer survivors in Southeast Asia: results from a longitudinal study in eight low-and middle-income countries. BMC medicine, 15(1), p.10.

Andronis, L., Goranitis, I., Bayliss, S. and Duarte, R., 2018. Cost-effectiveness of treatments for the management of bone metastases: A systematic literature review. PharmacoEconomics, 36(3), pp.301-322.

Botteman, M., Barghout, V., Stephens, J., Hay, J., Brandman, J. and Aapro, M., 2006. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Annals of oncology, 17(7), pp.1072-1082.

Carter, J.A., Joshi, A.D., Kaura, S. and Botteman, M.F., 2012. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours. Pharmacoeconomics, 30(5), pp.373-386.

Carter, J.A., Joshi, A., Kaura, S. and Botteman, M.F., 2011. Cost effectiveness of zoledronic acid in the management of skeletal metastases in hormone-refractory prostate cancer patients in France, Germany, Portugal, and the Netherlands. Journal of medical economics, 14(3), pp.288-298.

Coleman, R.E., 2006. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical cancer research, 12(20), pp.6243s-6249s.

Coleman, R.E., 1997. Skeletal complications of malignancy. Cancer: Interdisciplinary International Journal of the American Cancer Society, 80(S8), pp.1588-1594.

Consumer Price Guide. Pharmaceutical Services Programme, Ministry of Health Malaysia. Available at: https://www.pharmacy.gov.my/v2/en/apps/drug-price. (Accessed: 17 July 2018)

Dranitsaris, G., Truter, I., Lubbe, M.S., Sriramanakoppa, N.N., Mendonca, V.M. and Mahagaonkar, S.B., 2011. Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in Malaysia. The Malaysian journal of medical sciences: MJMS, 18(4), p.32.

Dranitsaris, G. and Hsu, T., 1999. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Supportive care in cancer, 7(4), pp.271-279.

Puteh, S.E.W., Junid, S.M.A.J.S., Khamis, N., Ahmed, Z., Sulong, S., Nur, A.M., Aizuddin, A.N., Ismail, F., Abdullah, N., Zainuddin, Z.M. and Kassim, A.Y.M., 2013. Skeletal-related events among breast and prostate cancer patients: Towards new treatment initiation in malaysia's hospital setting. Asian Pacific Journal of Cancer Prevention, 14(5), pp.3357-3362.

Ford, J., Cummins, E., Sharma, P., Elders, A., Stewart, F., Johnston, R., Royle, P., Jones, R., Mulatero, C., Todd, R. and Mowatt, G., 2013. Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Health Technology Assessment, 17(29):1-386.

Formulari Ubat Kementerian Kesihatan Malaysia. 2017. Accessed on : 13/2/2018. Available at: https://www.pharmacy.gov.my/v2/ms/apps/fukkm.

Hwa, Y.S., Shatar, A.K.A. and Hashim, H., 2011. THE SOCIOECONOMIC IMPACTS OF BREAST CANCER ON BREAST CANCER PATIENTS IN PENANG. Kajian Malaysia: Journal of Malaysian Studies, 29(2).

Lee, W.C., Haron, M.R., Yu, K.L., Chong, F.L.T., Goh, A. and Azmi, S., 2016. Economic analysis of intravenous vs. subcutaneously administered trastuzumab for the treatment of HER2+ early breast cancer in Malaysia. Advances in Breast Cancer Research, 5(01), p.1.

MOH Investigation Charges. Ministry of Health Malaysia. Accessed on 17/7/2018. Available at: http://www.moh.gov.my/english.php/pages/view/155

Nafees, B., Patel, C., Ray, D., Gray, E., Lau, H.J. and Lloyd, A.J., 2016. An Assessment of Health-State Utilities in Metastatic Breast Cancer in the United Kingdom. Value in Health, 19(3), p.A157.

National Institute for Health and Care Excellence (NICE), 2011. CG121: The diagnosis and the treatment of lung cancer (update). London: NICE.

National Institute for Health and Care Excellence (NICE), 2009. CG81: Advanced breast cancer: diagnosis and treatment. London: NICE.

National Institute for Health and Care Excellence (NICE), 2008. CG75: Metastatic spinal cord compression: diagnosis and management of patients at risk of or with metastatic spinal cord compression. London: NICE.

Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J.L., Vinholes, J.J., Goas, J.A. and Zheng, M., 2004. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute, 96(11), pp.879-882.

Xie, J., Namjoshi, M., Wu, E.Q., Parikh, K., Diener, M., Yu, A.P., Guo, A. and Culver, K.W., 2011. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. Journal of Managed Care Pharmacy, 17(8), pp.621-643.

Zainal, R. and Mahat, M., 2014. Estimating The Costs Of Specialist Out-Patient Services In A Public Hospital. Value in Health, 17(7), p.A790.

Zainal Ariffin, O., and I. T. Nor Saleha, 2011. “National cancer registry report 2007.” Malaysia: Ministry of Health. Accessed on 23 July 2018.

Downloads

Published

2019-11-25

How to Cite

KAMARUZAMAN, H. F., Shaharudin, A., Wan Puteh, S. E., Ahmed, Z., & Sabirin, J. (2019). BONE TARGETING AGENTS IN PREVENTION OF SKELETAL-RELATED EVENTS IN METASTATIC CANCERS OF SOLID TUMOURS: AN ECONOMIC EVALUATION. Proceedings of the International Conference on Public Health, 5(1), 08–20. https://doi.org/10.17501/23246735.2019.5102

Issue

Vol. 5 No. 1 (2019): Proceedings of the International Conference on Public Health

Section

Articles

License

The Conference Proceedings of International Conference on Public Health is entirely Open Access, which means that all published content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this Proceedings journal without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

Authors who publish with Conference Proceedings agree to the following terms:

    1. Authors retain copyright and grant the Proceedings of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this conference proceedings.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the proceeding's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this conference proceedings.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

Licensing

Creative Commons License
Published articles are licensed under a Creative Commons Attribution 4.0 International License.